Barrett & Company’s ARK Genomic Revolution ETF ARKG Stock Holding History

Barrett & Company’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$661	Hold	25	–	–	﹤0.01%	625
2025 Q4	$724	Hold	25	–	–	﹤0.01%	631
2025 Q3	$694	Hold	25	–	–	﹤0.01%	617
2025 Q2	$609	Hold	25	–	–	﹤0.01%	619
2025 Q1	$519	Hold	25	–	–	﹤0.01%	599
2024 Q4	$589	Hold	25	–	–	﹤0.01%	594
2024 Q3	$640	Hold	25	–	–	﹤0.01%	559
2024 Q2	$587	Hold	25	–	–	﹤0.01%	577
2024 Q1	$719	Hold	25	–	–	﹤0.01%	586
2023 Q4	$820	Hold	25	–	–	﹤0.01%	575
2023 Q3	$697	Hold	25	–	–	﹤0.01%	588
2023 Q2	$852	Hold	25	–	–	﹤0.01%	568
2023 Q1	$752	Hold	25	–	–	﹤0.01%	555
2022 Q4	$706	Hold	25	–	–	﹤0.01%	560
2022 Q3	$706	Buy	+25	New	+$918	﹤0.01%	560

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Barrett & Company's ARKG Position: Q1 2026 in Review

Barrett & Company held its ARK Genomic Revolution ETF (ARKG) position steady in Q1 2026 at 25 shares worth $661. The position accounts for ﹤0.01% of the portfolio, ranked #625.

Barrett & Company first reported a position in ARKG in Q3 2022 and has held it in 15 quarters since. The position peaked at $852 in Q2 2023. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Barrett & Company held 25 shares of ARK Genomic Revolution ETF worth $661 as of Q1 2026.
Barrett & Company left its ARK Genomic Revolution ETF share count unchanged in Q1 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Barrett & Company's portfolio in Q1 2026, its #625 holding.
Barrett & Company first reported a position in ARK Genomic Revolution ETF in Q3 2022 and has held it in 15 quarters since.
Barrett & Company's ARK Genomic Revolution ETF position peaked at $852 in Q2 2023.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.